Drug Design, Development and Therapy (Feb 2020)
Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A
Abstract
Sandra Le Quellec1,2 1Unité d’hémostase Clinique – Hôpital Cardiologique Louis Pradel – Hospices Civils de Lyon, Lyon, France; 2Service d’hématologie biologique, Groupement Hospitalier Est – Hospices Civils de Lyon, Lyon, FranceCorrespondence: Sandra Le QuellecUnité d’Hémostase Clinique, Hôpital Cardiologique Louis Pradel, 59, boulevard Pinel, Bron 69677, FranceTel +33 4 72 11 88 10Fax +33 4 72 11 88 17Email [email protected]: Emicizumab is a bispecific, humanized, monoclonal antibody mimicking the factor (F) VIII cofactor activity in mediating the generation of FXa by FIXa in patients with hemophilia A (HA). This subcutaneous non-factor agent has been recently extensively approved for the prophylaxis of patients of HA patients with and without FVIII-inhibitors of all ages, although few data are currently available in children. In Phase 3 clinical trials and case series, emicizumab prophylaxis significantly reduced bleeding rates compared to previous treatment in HA adolescents and children with or without FVIII-inhibitors and was generally well tolerated. In addition, subcutaneous administration of emicizumab provided beneficial effects on health-related quality of life, and lessened the burden of the disease in HA patients as well as in their caregivers. However, additional prospective studies are required to evaluate the long-term safety of emicizumab prophylaxis in very young patients, including previously untreated patients. The aim of this paper was to review the limited data available on the use of emicizumab prophylaxis in children and to highlight the need for further studies to address remaining concerns.Keywords: emicizumab, hemophilia A, inhibitors, factor VIII, prophylaxis, subcutaneous
